Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) shares, rose in value on Friday, June 20, with the stock price down by -3.08% to the previous day’s close as strong demand from buyers drove the stock to $24.56.
Actively observing the price movement in the last trading, the stock closed the session at $25.34. The PE ratio was 8.91 over 12-month period. Referring to stock’s 52-week performance, its high was $53.96, and the low was $22.64. On the whole, AMPH has fluctuated by -2.03% over the past month.
With the market capitalization of Amphastar Pharmaceuticals Inc currently standing at about $1.16 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AMPH’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of AMPH currently trading nearly -4.23% and -0.80% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.37, while the 7-day volatility ratio is showing 1.54% which for the 30-day chart, stands at 1.98%. Furthermore, Amphastar Pharmaceuticals Inc (AMPH)’s beta value is 0.76, and its average true range (ATR) is 0.82.
A comparison of Amphastar Pharmaceuticals Inc (AMPH) with its peers suggests the former has fared considerably weaker in the market. AMPH showed an intraday change of -3.08% in last session, and over the past year, it shrunk by -39.42%%.
Data on historical trading for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) indicates that the trading volumes over the past 3 months, they’ve averaged 577.58K. According to company’s latest data on outstanding shares, there are 47.67 million shares outstanding.
Nearly 26.23% of Amphastar Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 72.37% of the company’s shares. The stock has fallen by -33.85% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AMPH stock heading into the next quarter.
